Category Archives: Global News Feed

WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell quarterly update, effective December 21, 2020.

View original post here:
C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target.

Excerpt from:
NextCure Provides Updates on NC318 Clinical Program

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products in women’s health, today announced that it is expanding the availability of COVID-19 RT-PCR testing across the United States to support the rising demand for testing.

Original post:
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States

Read the rest here:
Kolab Project Launches 232 Series Limited Edition Live Terpene 510 Vape Cartridges

Partnership with Alliancepharma Technologies S.A., one of Ecuador’s largest pharmaceutical companies, will take advantage of the upcoming cannabis regulations to allow for the registration and distribution of several of Avicanna’s consumer and pharmaceutical products across Ecuador

Continued here:
Avicanna Expands Distribution Network in South America Through Commercial Partnerships in Ecuador and Commercial Export of Feminized Seeds to Uruguay

WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further support development of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021. Data were presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting, Dec. 5-8, 2020 in three separate poster presentations.

Originally posted here:
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

Data support a planned clinical trial of NX-2127 in B-cell malignancies Data support a planned clinical trial of NX-2127 in B-cell malignancies

Read more from the original source:
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of a clinical data set on AFM13 at the 62nd American Society of Hematology Annual Meeting and Exposition. Dr. Ahmed Sawas, Assistant Professor of Medicine at Columbia University College of Physicians and Surgeons and the New York-Presbyterian Hospital, and principal investigator presented the updated results of a phase 1b/2a study in patients with CD30-expressing lymphoma with cutaneous involvement.

See the article here:
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a...

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumab plus chlorambucil (HR=0.54, p<0.0001) as well as ORR (p<0.001) in patients with CLL; with consistent PFS improvement across treatment naïve CLL (HR=0.48) and relapsed/refractory CLL (HR=0.60)

Original post:
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual...

myCare-021-04 study finds genetic signatures associated with 100% remission rate fromAML induction therapy despite presence of Monosomy 7

See the original post here:
Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with Monosomy 7